Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron shares up 1.4% premarket after earnings top estimates
06:47am, Wednesday, 04'th May 2022
Regeneron Pharmaceuticals Inc. shares REGN, +1.30% rose 1.4% in premarket trade Wednesday, after the company beat consensus estimates for the first quarter. The company posted net income of $974 milli
5 Graham's Lost Formula Biotech Stocks to Consider for May
04:35pm, Tuesday, 03'rd May 2022
After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.
Regeneron Announces Investor Conference Presentations
04:15pm, Monday, 02'nd May 2022
TARRYTOWN, N.Y. , May 2, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities Healthcare Conference at 1:20 p.m.
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
09:11am, Friday, 29'th Apr 2022
Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
Many Big Pharma Stocks Have Outperformed. It Isn't Too Late to Buy.
03:49pm, Thursday, 28'th Apr 2022
The companies' earnings don't depend on the strength of the economy. Drug demand doesn't waver when consumers tighten their budgets.
Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M
12:47pm, Wednesday, 20'th Apr 2022
Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.
3 Top Biotech Stocks Ready for a Bull Run
07:40am, Wednesday, 20'th Apr 2022
The hype has died down. Now it's time for science to take over.
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
09:13am, Tuesday, 19'th Apr 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Check
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
01:32pm, Monday, 18'th Apr 2022
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
3 Fantastic Biotech Stocks to Buy in April
06:04am, Monday, 18'th Apr 2022
These stocks are bright spots in an overall dismal market for biotech stocks.
Regeneron says FDA is still evaluating whether to fully approve its COVID-19 treatment
07:57am, Thursday, 14'th Apr 2022
Regeneron Pharmaceuticals Inc. REGN, +2.25% said Thursday that the Food and Drug Administration extended the review time by three months on whether to fully approve Regen-Cov as a treatment for non-ho
Antibody Treatments for COVD-19 Face Challenges in the U.S.
10:32am, Friday, 08'th Apr 2022
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids
04:34pm, Thursday, 07'th Apr 2022
Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.
BioPharma Giants Print Fresh All-Time Highs
03:48pm, Thursday, 07'th Apr 2022
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?
01:33pm, Wednesday, 06'th Apr 2022
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
